IgG4:IgG RNA ratio differentiates active disease from remission in granulomatosis with polyangiitis: a new disease activity marker? A cross-sectional and longitudinal study

Autor: A. Al-Soudi, M. E. Doorenspleet, R. E. Esveldt, L. T. Burgemeister, A. E. Hak, B. J. H. van den Born, S. W. Tas, R. F. van Vollenhoven, P. L. Klarenbeek, N. de Vries

Publikováno v: Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-11 (2019)

Abstract Objectives An important limitation in granulomatosis with polyangiitis (GPA) is the lack of disease activity markers. Immunoglobulin G4-positive (IgG4+) B cells and plasma cells are implicated in the pathogenesis of GPA. We hypothesized that

Externí odkaz: https://doaj.org/article/97fc3ae57f064f7ca6b4cc620dcc70d8

Disease activity in women with ankylosing spondylitis remains higher under Tumour Necrosis Factor inhibitor treatment than in men:a five-year observational study

Autor: M M Ter Wee, T. Rusman, C. van Denderen, S.E. Hoekstra, Michael T Nurmohamed, R. F. van Vollenhoven, I E van der Horst-Bruinsma, Maarten Boers

Publikováno v: Rusman, T, Nurmohamed, M T, Hoekstra, S, van Denderen, C J, van Vollenhoven, R F, Boers, M, Ter Wee, M M & van der Horst-Bruinsma, I E 2021, ' Disease activity in women with ankylosing spondylitis remains higher under Tumour Necrosis Factor inhibitor treatment than in men : a five-year observational study ', Scandinavian Journal of Rheumatology . https://doi.org/10.1080/03009742.2021.1967046
Scandinavian Journal of Rheumatology, 51, 6, pp. 506-512
Scandinavian Journal of Rheumatology, 51, 506-512
Scandinavian journal of rheumatology. Informa Healthcare
Scandinavian Journal of Rheumatology. Informa Healthcare

Contains fulltext : 287604.pdf (Publisher’s version ) (Open Access) OBJECTIVE: To assess sex differences in response, level of disease activity, and drug survival in tumour necrosis factor inhibitor (TNFi)-naïve ankylosing spondylitis (AS) patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9788d53daff685843ec0b08b3bca3e4b
https://research.vumc.nl/en/publications/13b76a5e-bf90-41a4-8fe9-89be6679afc2

Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis

Autor: Gertjan Wolbink, R. F. van Vollenhoven, J. Ruwaard, Michael T. Nurmohamed, M. J. L `Ami, Theo Rispens, C. Krieckaert

Publikováno v: l’ Ami, M J, Ruwaard, J, Krieckaert, C L M, Nurmohamed, M T, van Vollenhoven, R F, Rispens, T & Wolbink, G J 2019, ' Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis ', Scandinavian Journal of Rheumatology, vol. 48, no. 4, pp. 266-270 . https://doi.org/10.1080/03009742.2019.1577915
Scandinavian journal of rheumatology, 48(4), 266-270. Informa Healthcare
Scandinavian Journal of Rheumatology, 48(4), 266-270. Informa Healthcare

Objectives: Inadequate response to adalimumab can be caused by insufficient blockade of the target tumour necrosis factor (TNF) at low serum concentrations. In such cases, patients may respond to another TNF inhibitor. We investigated whether the ser

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c6026d3d2ac45b0b1a3444ac07ba119
https://research.vumc.nl/en/publications/7d684d16-22f2-43fb-8e77-df1af7b17746

SAT0189 Dynamics of circulating tnf during adalimumab treatment of rheumatoid arthritis using a novel drug-tolerant tnf assay

Autor: T. Rispens, G.J. Wolbink, R. F. van Vollenhoven, M. Hart, Catherine H. Smith, Karien Bloem, Merel J l'Ami, Lea C. Berkhout, Michael T. Nurmohamed, P. Ooijevaar-de Heer, J. Ruwaard, Maarten Boers

Publikováno v: Saturday, 16 JUNE 2018.

Background: Tumor necrosis factor- (TNF) inhibitors are effective in the treatment of rheumatoid arthritis (RA); these include adalimumab, which binds TNF to form inactive complexes. Once in remission, a proportion of patients can successfully discon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d7de059beb175aa18b379794c931561f
https://doi.org/10.1136/annrheumdis-2018-eular.3749

Gender Differences in Axial Spondyloarthritis

Autor: Tamara Rusman, I E van der Horst-Bruinsma, R. F. van Vollenhoven

Publikováno v: Rusman, T, van Vollenhoven, R F & van der Horst-Bruinsma, I E 2018, ' Gender Differences in Axial Spondyloarthritis : Women Are Not So Lucky ', Current Rheumatology Reports, vol. 20, no. 6, 35 . https://doi.org/10.1007/s11926-018-0744-2
Current Rheumatology Reports

Purpose of Review: Ankylosing spondylitis (AS) was historically seen as a predominantly male disease. However, more recent data showed a more homogenous sex prevalence. Unfortunately, in many studies in axial spondyloarthritis (axSpA), the number of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29b37b3cf3e07ec3467211ea1d532be3
https://doi.org/10.1007/s11926-018-0744-2